Can-Fite Secures Israeli Patent for A3AR Agonist Namodenoson Obesity Treatment
Can-Fite BioPharma received Israeli patent allowance for using Namodenoson as an A3 adenosine receptor agonist to induce fat loss and treat obesity, expanding protection established in the US, Canada and Australia. The global obesity therapeutics market is projected to reach $60.5 billion by 2030 at a 22% CAGR.
1. Patent Allowance in Israel
Can-Fite has secured allowance of Israeli patent No. 284463 covering use of A3 adenosine receptor agonists such as Namodenoson to induce fat loss and treat obesity and related metabolic disorders. This milestone extends the company’s global intellectual property coverage following similar approvals in the United States, Canada and Australia.
2. Namodenoson’s Mechanism and Data
Namodenoson is a highly selective, orally bioavailable A3AR agonist that targets pathways in adipogenesis, inflammation and metabolic regulation. Preclinical and early clinical studies have demonstrated its potential to reduce fat accumulation and improve metabolic profiles while maintaining an established safety record.
3. Market Opportunity and Strategy
The global obesity therapeutics market is projected to reach $60.5 billion by 2030 at a 22% CAGR, driven by rising disease prevalence and demand for safe oral therapies. Strengthened IP protection positions Can-Fite to pursue partnerships and further development in this rapidly expanding segment.